Abstract
Intracoronary infusion of [4Cl-D-Phe6-Leu17]VIP caused modest significant inhibition of the coronary vasodilation produced by intraarterial VIP, but did not significantly inhibit serotonin-induced coronary vasodilation. In addition, infusion of [4Cl-D-Phe6-Leu17]VIP did not result in significant changes in baseline coronary resistance, heart rate or left ventricular dP/dt. These findings demonstrate that [4Cl-D-Phe6-Leu17]VIP is a competitive antagonist of VIP-induced vasodilation in the canine coronary circulation, but fail to demonstrate a significant role for VIP in the regulation of resting coronary vasomotor tone, and do not support the hypothesis that VIP is a mediator of serotonin-induced coronary arteriolar dilation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Blood Pressure / drug effects
-
Coronary Circulation / drug effects*
-
Coronary Vessels / drug effects
-
Coronary Vessels / physiology*
-
Dogs
-
Female
-
Heart Rate / drug effects
-
Infusions, Intra-Arterial
-
Male
-
Muscle, Smooth, Vascular / drug effects
-
Muscle, Smooth, Vascular / physiology
-
Reference Values
-
Serotonin / administration & dosage
-
Serotonin / pharmacology*
-
Vasoactive Intestinal Peptide / administration & dosage
-
Vasoactive Intestinal Peptide / analogs & derivatives*
-
Vasoactive Intestinal Peptide / antagonists & inhibitors
-
Vasoactive Intestinal Peptide / pharmacology*
Substances
-
vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-
-
Serotonin
-
Vasoactive Intestinal Peptide